Roivant Sciences Director Meghan Fitzgerald Receives Annual Director Equity Awards
Roivant Sciences Ltd.
Subscribe to track ROIV
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
=== SEC FORM 4 INSIDER FILING ===
Company: Roivant Sciences Ltd. (ROIV)
Insider: Meghan Fitzgerald
Role: Director
Filing Date: 2026-09-18
Event Date: 2026-09-16
Type: Award / Grant (Code: A)
Shares: 5,054 RSUs ($0.00)
Options: 10,531 options @ $39.57
Ending Hold: 41,162 common shares
Significance:Low (Routine Director Compensation)
Comprehensive Analysis
Executive Summary
On September 18, 2026, Roivant Sciences Ltd. (ROIV) filed a Form 4 disclosing that Director Meghan Fitzgerald received annual equity awards under the company's 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy. The awards, granted on September 16, 2026, comprise 5,054 restricted stock units (RSUs) and 10,531 stock options.
Transaction Details
- Non-Derivative Award: 5,054 RSUs granted at $0 per share, scheduled to vest 100% on September 16, 2027, contingent upon continued board service. Following this grant, direct ownership rose to 41,162 common shares.
- Derivative Award: 10,531 stock options to purchase common shares with an exercise price of $39.57 per share, vesting 100% on September 16, 2027, and expiring on September 15, 2036.
Market & Strategic Significance
This filing represents standard, scheduled annual equity compensation for an independent director rather than discretionary open-market buying or selling. Because the transaction represents routine equity-based compensation structured under established board policies, it carries low predictive signal regarding near-term operational changes or equity valuation.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.